Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Genetic Disease

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Hemophilia Clinical Trials

A listing of Hemophilia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (61) clinical trials

Non Substitutive Strategies to Improve Haemophilia Care in Developing Countries. Experience in Ivory Coast.

Establish a baseline of the condition of haemophilia in Ivory Coast (number of patients, demographics, reassessment of diagnosis, joint status...).(year 1) Develop tools to assess the intervention (eg transcultural validation of QoL questionnaires, develop booklets to record bleedings...). (year 1) Intervention phase that will focus on education of patients and ...

Phase N/A

rVWF IN PROPHYLAXIS

The purpose of this phase 3 study is to investigate the efficacy and safety, including immunogenicity and thrombogenicity of prophylactic treatment with recombinant von Willebrand factor (rVWF) in subjects with severe von Willebrand disease (VWD).

Phase

A Factor IX Gene Therapy Study (FIX-GT)

Severe haemophilia B is a bleeding disorder where a protein made by the body to help make blood clot is either partly or completely missing. This protein is called a clotting factor; with severe haemophilia B, levels of clotting factor IX (FIX) (nine) are very low and affected individuals can ...

Phase

Gene Therapy for Haemophilia A.

Haemophilia A is an x-linked, life threatening bleeding disorder arising from defects in the coagulation factor VIII (FVIII) gene. Current treatment for haemophilia A, the commonest inherited bleeding disorder (prevalence of 1 in 5000 individuals) consists of life-long, 2-3X/week, intravenous injection of clotting factor concentrates, which is demanding, exceedingly expensive ...

Phase

Prospective Biomarkers of Bone Metabolism in Hemophilia A

This is a pilot study to determine the impact of factor replacement on bone biomarkers in up to 20 hemophilia A subjects. Subjects will be recruited over 1 year for the 5-day protocol. Following a 72-hour washout period, factor levels and bone biomarkers will be followed before and after 50 ...

Phase

Evaluate Efficacy and Safety of Recombinant Factor VIII rFVIII Treatment of Severe or Moderately Severe Hemophilia A

Efficacy, Safety and Pharmacokinetics Study of a rFVIII in Chinese subjects with Hemophilia A.To assess efficacy and safety of rFVIII administered as treatment and as on-demand therapy in adult and adolescent (12-65 years) patients with severe or moderately severe Hemophilia A. To determine the pharmacokinetic (PK) parameters of rFVIII.

Phase

Comparison of Ideal vs. Actual Weight Base Factor Dosing

This is a randomized, prospective, multicenter, open-label, crossover study to examine whether or not the current recommended factor dosing strategy, i.e., dosing by actual body weight in overweight and obese patients, may deliver more clotting factor than necessary to cause bleeding to stop in participants with Hemophilia A who use ...

Phase N/A

A Clinical Phenotype Based Individualized Prophylaxis in Chinese Hemophilia A Children

In the past, due to economic and medical resource constraints, the hemophilia comprehensive care in China was suboptimal. The BCH data of both retrospective and prospective studies reveals that for 4-6y and 6-9y patients with severe hemophilia respectively: 45% and 82% of the patients have suffered from joint bleeding, with ...

Phase

DDAVP vs. Exercise in Patients With Mild Hemophilia A

Persons with mild hemophilia A (MHA) (defined as having a FVIII level of >5% to 40%) bleed infrequently but can in the setting of trauma which can often is in the context of participating in sports/exercise. FVIII levels temporarily rise with stress, exercise and with DDAVP (1-desamino-8-D-arginine vasopressin, desmopressin). In ...

Phase

A Phase III Study on the Safety Pharmacokinetics and Efficacy of Coagulation Factor VIIa

A Phase III Study on the Safety, Pharmacokinetics, and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Pediatric Patients from birth to <12 years old with Inhibitors to Factor VIII or IX: PerSept 2

Phase